Sanjeev Valentine的动态

The Global Fetal and Neonatal Care Equipment?Market was valued at USD 8,623.1 million?in 2023 and is expected to reach USD 13,847.9 million?by 2031 while growing at a CAGR of 6.1%?during the forecast period (2024-2031). Download a free sample: https://rb.gy/axsrj7 A few of the leading players operating in the market are Inspiration Healthcare, Medtronic, Philips, Dr?ger, Rocket Medical, Masimo, ATOM Medical USA, Vyaire Medical, and Arjo #fetalequipmentmarket #neonatalequipmentmarket #fetalequipmentmarketsize #fetalequipmentmarketshare #fetalequipmentmarketopportunity, #neonatalmarketsize #fetaldopplermarketsize #neonatalequipmentmarketgrowth #fetalandneonatalmarket

Exciting news today as Biosense Webster receives European CE mark approval for our VARIPULSE? Platform, marking a significant step forward in treating cardiac arrhythmia with pulsed field ablation (PFA) technology. With estimates suggesting that by 2050, Europe will have the greatest increase in Atrial Fibrillation compared to other regions globally, this milestone not only signifies our commitment to innovation in cardiac care but also positions us here in Europe at the forefront of solving some of the most pressing challenges in cardiac care. Our focus now is working alongside physicians and healthcare providers, together with our leading clinical teams throughout the region to bring this technology to all those patients who can benefit. https://lnkd.in/edYARrJz #myCompany #CardiacCare #JNJMedTechProud #VARIPULSE #PulsedFieldAblation

We’re thrilled to share that our subsidiary,?Kardiolytics Inc, has been granted a new patent in the United States, marking a significant milestone in our journey towards revolutionizing cardiac care. The patent, numbered?US20240120110A1, recognizes our method of numerical modeling of blood flow in arteries—a vital component of our?#VCAST?technology. What does this mean for healthcare? ?? Our patented method allows for precise analysis of arterial blood flow, enabling clinicians to assess atherosclerotic plaque surface deformation and stress—an invaluable tool in diagnosing coronary artery disease. Przemek Tadla, CTO at?Medicalgorithmics?and COO at?Kardiolytics, shares his thoughts: “This new patent underscores the medical and commercial potential of the VCAST technology. It highlights our innovation and strengthens the competitive edge and protection of our technology.” But that’s not all! ?? We’re also making strides in regulatory approval processes. With?CE certification initiation?in the EU and plans for?FDA approval?in the US, we’re on track to bring VCAST to patients worldwide, offering a non-invasive, hospitalization-free diagnostic solution for coronary artery disease. Stay tuned as we continue to push the boundaries of innovation in cardiac care with VCAST technology: https://lnkd.in/eSMWKcts #Medicalgorithmics #VCAST #Innovation #CardiacCare #HealthTech

?? Johnson & Johnson MedTech’s Impella ECP shows safety and efficacy in IDE study The IDE study is the first clinical trial completed on patients supported with Impella ECP, a novel transvalvular axial flow pump with compressible pump architecture. Impella ECP technology is developed by Abiomed, a company of Johnson & Johnson MedTech. The IDE study established the safety and efficacy of Impella ECP in high-risk percutaneous coronary intervention (PCI), with a major adverse cardiac and cerebrovascular events (MACCE) rate of 6.3%. Read more online: https://lnkd.in/e9_MiTst ?? Follow Medical Device Developments to receive the latest medical device news daily and to subscribe to our weekly newsletter #MedicalDeviceDevelopments #medicaldevices #medicalmanufacturing

Why the Shockwave Deal is Great News for Everyone ?? In a remarkable move, healthcare behemoth Johnson & Johnson has committed an additional $13B into their MedTech division, with a primary focus on cardiovascular health. ?? The company has inked a significant deal with Shockwave Medical, a specialist in technology designed to unclog arteries. ?? Founded in 2009, Shockwave Medical has been at the forefront of intravascular lithotripsy technology, utilizing sonic pressure waves to break down calcium lesions in our arteries and restore optimal blood flow. ?? This ingenious approach draws parallels with techniques employed to fragment kidney stones. A truly game-changing innovation in the treatment of both coronary artery and peripheral artery disease. ?? This strategic acquisition clearly illustrates the attractiveness of the MedTech industry, with multinationals like J&J willing to invest substantial resources. The fact that Shockwave's revenue saw an impressive 49% increase last year to $730 million further underlines the potential of this flourishing sector. ?? With the increasing investment in MedTech, how do you see this industry evolving in the future? What are the key trends we should look out for? #HealthcareInnovation #MedTech #JohnsonAndJohnson #ShockwaveMedical

US HCPs: ? Listen to Dr. Frank Arko talk about improving ALI outcomes using an endovascular first approach with #LightningBolt7. #CAVT ? Rx only. Risk info: peninc.info/risk Clinical results may vary

?? Exciting News from Endoron Medical! ?? We are thrilled to share that Endoron Medical has achieved a major milestone by expanding our reach to the United States with the acquisition of a new patent. ?? Our cutting-edge endostapling technology is set to revolutionize the landscape of Abdominal Aortic Aneurysm (AAA) treatment through EndoVascular Aneurysm Repair (EVAR). While EVAR already presents an operative mortality advantage over open repair, long-term survival benefits have often been elusive due to durability challenges with existing endografts. Enter Aortoseal - Endoron’s groundbreaking solution that not only offers patients a minimally invasive procedure but also ensures a sustained survival advantage, coupled with fewer complications and reinterventions. This achievement signifies a pivotal moment in our journey, emphasizing our commitment to innovation and our aspiration for a global impact. Join us in celebrating this step forward in advancing healthcare solutions for AAA patients worldwide! #EndoronMedical #InnovationInHealthcare #AAA #EVAR #GlobalHealthcareSolution #AAA??

Penumbra, Inc. Revolutionizes Clot Removal with Lightning Flash 2.0 Exciting news in the world of cardiovascular care! Penumbra, a leading medical device company, has announced the FDA approval and commercialization of its latest innovation, the Lightning Flash 2.0 system. Lightning Flash 2.0 is the next-generation computer-assisted vacuum thrombectomy (CAVT) system designed to rapidly remove venous thrombus and treat pulmonary emboli (PE). Featuring advanced algorithms for increased speed and sensitivity, this system, combined with Penumbra's novel catheter technology, empowers physicians to navigate complex anatomy and deliver superior clot removal with minimal blood loss. According to Penumbra's FSIR chief medical officer, James F. Benenati, M.D., FSIR, "Lightning Flash 2.0 has significantly improved procedure time by shortening the aspiration time and shown reductions in blood removed during aspiration. These advantages can improve patient safety, provide better outcomes, and streamline efficiency for physicians."As the only computer-assisted mechanical thrombectomy systems currently available in the US, Penumbra's Lightning family of products continues to push the boundaries of cardiovascular care. With the launch of Lightning Flash 2.0, the company reaffirms its commitment to advancing patient care and ensuring more individuals can benefit from this transformative technology. https://lnkd.in/eAKaenfB Be sure to follow?Practical Patient Care?on LinkedIn for more industry news and insights. #PracticalPatientCare #MedicalDevices #CardiovascularCare #ThrombectomyInnovation

??? Navigate regulatory challenges?with Fivos. Explore some of our past #vascular and #neurovascular projects to see how you too can unlock new device potential — https://lnkd.in/gUY_Pc-4. #EUMDR #LabelExpansion #ExternalControlArms #PropensityScoreMatching #CoreLabIntegration #RWE